Stockscreener 앱 받기
42.65
1.20%
-0.52
시간 외 거래:
41.89
-0.76
-1.78%
전일 마감가:
$43.17
열려 있는:
$43.65
하루 거래량:
1.56M
Relative Volume:
0.57
시가총액:
$5.66B
수익:
-
순이익/손실:
$-237.54M
주가수익비율:
-17.04
EPS:
-2.5033
순현금흐름:
$-145.05M
1주 성능:
-0.35%
1개월 성능:
-5.12%
6개월 성능:
+143.99%
1년 성능:
+0.00%
1일 변동 폭
$41.73
$45.42
1주일 범위
$41.57
$45.42
52주 변동 폭
$14.62
$49.20
Definium Therapeutics Inc Stock (DFTX) Company Profile
명칭
Definium Therapeutics Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
42.65 | 5.73B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Stifel | Buy |
| 2026-04-10 | 개시 | Piper Sandler | Overweight |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-30 | 개시 | Jefferies | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-08-04 | 재개 | Oppenheimer | Outperform |
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
DFTX Initiates Coverage On Wells Fargo -- Rating Set to Overweig - GuruFocus
Wells Fargo Initiates Definium Therapeutics at Overweight - marketscreener.com
DFTX Reiterated by Piper Sandler -- Price Target Raised to $73.0 - GuruFocus
Piper Sandler raises Definium stock price target on DT120 outlook By Investing.com - Investing.com South Africa
Piper Sandler raises Definium stock price target on DT120 outlook - Investing.com UK
Piper Sandler Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $73 - Moomoo
DEFINIUM THERAPEUTICS INC : PIPER SANDLER RAISES TARGET PRICE TO $73 FROM $48 - Bitget
Definium Therapeutics (DFTX) Highlights GAD Care Gaps, Is The Stock Already Overvalued? - Yahoo Finance
How New GAD Treatment Gap Data At Definium Therapeutics (DFTX) Has Changed Its Investment Story - Yahoo Finance
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics Inc. (DFTX) Fundamental & Financial Data - Stocktwits
Definium Therapeutics Announces New Employee Inducement Grants - The Globe and Mail
Definium Therapeutics, Inc. (DFTX) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Why Is GH Research Stock Trading Higher on Thursday? - Benzinga
Analysts Are Bullish on Top Healthcare Stocks: Staar Surgical (STAA), Definium Therapeutics (DFTX) - The Globe and Mail
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology - Times Argus
Definium Therapeutics Inc. (DFTX) News, Articles, Events & Latest Updates - Stocktwits
LifeSci Capital Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $63 - Moomoo
Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data? - Yahoo Finance
Definium Therapeutics (DFTX) Could Be 30% Overvalued After New GAD Study - Sahm
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet - Yahoo Finance
Definium Therapeutics, Inc. Announces Results from New Healthcare Claims Study of Treatment Patterns of Newly Diagnosed and Established Gad Patients, Including Pharmacotherapy Use, Discontinuation, Switching and Treatment Progression - marketscreener.com
Why is Definium Therapeutics stock rallying today? By Investing.com - Investing.com Nigeria
More Than Half of Newly Diagnosed GAD Patients Stopped Therapy - Stock Titan
Definium Therapeutics eyes key DT-120 depression data, advances anxiety program - MSN
DFTX Inc. Stock (DFTX) Opinions on Phase 3 Results and Offering - Moomoo
Why is Definium Therapeutics stock rallying today? - Investing.com
Definium Therapeutics (DFTX) Following Russell Index Removal And The Fair Value Debate - Sahm
Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Raises Target Price to $60 - Moomoo
Stifel raises Definium Therapeutics price target on MDD data By Investing.com - Investing.com Nigeria
Stifel raises Definium Therapeutics price target on MDD data - Investing.com
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering - AOL.com
Earnings call transcript: Definium’s Q1 2026 EPS miss overshadows strategic advances - Investing.com
Positive Phase 3 DT120 ODT Results in Depression Could Be A Game Changer For Definium Therapeutics (DFTX) - Sahm
Definium earnings on deck as pivotal psychedelic trial data looms By Investing.com - Investing.com India
DFTXDefinium Therapeutics Inc Volatility & Greeks - Finviz
Definium Therapeutics Inc (DFTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):